Search

Your search keyword '"Garcia-Corbacho, J."' showing total 107 results
Start Over Author "Garcia-Corbacho, J."
107 results on '"Garcia-Corbacho, J."'

1. A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

Author

Hamilton, E., Oliveira, M., Turner, N., García-Corbacho, J., Hernando, C., Ciruelos, E.M., Kabos, P., Ruiz-Borrego, M., Armstrong, A., Patel, M.R., Vaklavas, C., Twelves, C., Boni, V., Incorvati, J., Brier, T., Gibbons, L., Klinowska, T., Lindemann, J.P.O., Morrow, C.J., Sykes, A., and Baird, R.D.

Published
2024
Full Text
View/download PDF

4. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

Author

Pant, S, Schuler, M, Iyer, G, Witt, O, Doi, T, Qin, S, Tabernero, J, Reardon, D, Massard, C, Minchom, A, Lugowska, I, Carranza, O, Arnold, D, Gutierrez, M, Winter, H, Stuyckens, K, Crow, L, Najmi, S, Hammond, C, Thomas, S, Santiago-Walker, A, Triantos, S, Sweiti, H, Loriot, Y, Greco, M, Coward, J, Joshua, A, Karapetis, C, Hart, C, Zhang, A, Prenen, H, Goeminne, J, Machiels, J, Rottey, S, Corassa, M, Molin, G, Tiscoski, K, Jardim, D, Mak, M, Fu, W, Yao, H, Huang, J, Jiang, H, Chen, B, Yan, D, Yang, Y, Le Tourneau, C, Penel, N, Salas, S, Blay, J, Brachet, P, Durando, X, Emambux, S, Ravaud, A, Folprecht, G, Ahrens, M, Golf, A, Haag, G, Lordick, F, Desuki, A, Cazzaniga, M, Ciardiello, F, Milella, M, Koyama, T, Hirooka, Y, Okamoto, W, Aogi, K, Kuboki, Y, Lee, J, Kim, S, Ahn, M, Chang, J, Kim, Y, Nam, D, Park, J, Paz-Ares, L, Moreno, V, Cervantes, A, Calvo, M, Falcon, A, Gonzalez, A, Martinez Bueno, A, Garcia-Corbacho, J, Longo, F, Yen, C, Chen, J, Hou, M, Chao, Y, Rau, K, Chiu, T, Feng, Y, Hsu, C, Huang, W, Lai, K, Yeh, S, Palmer, D, Welsh, L, Plummer, R, Bilen, M, Arrowsmith, E, Spigel, D, Zandberg, D, Doroshow, D, Lu-Emerson, C, Moezi, M, Paulson, S, Ward, P, Chaves, J, Grigg, C, Hussein, A, Manda, S, Monticelli, M, Qamar, R, Richey, S, Tamura, D, Wilks, S, Pant S., Schuler M., Iyer G., Witt O., Doi T., Qin S., Tabernero J., Reardon D. A., Massard C., Minchom A., Lugowska I., Carranza O., Arnold D., Gutierrez M., Winter H., Stuyckens K., Crow L., Najmi S., Hammond C., Thomas S., Santiago-Walker A., Triantos S., Sweiti H., Loriot Y., Greco M. A., Coward J., Joshua A., Karapetis C., Hart C., Zhang A., Prenen H., Goeminne J. -C., Machiels J. -P., Rottey S., Corassa M., Molin G. Z. D., Tiscoski K., Jardim D. L. F., Mak M., Fu W., Yao H., Huang J., Jiang H., Chen B., Yan D., Yang Y., Le Tourneau C., Penel N., Salas S., Blay J. -Y., Brachet P. -E., Durando X., Emambux S., Ravaud A., Folprecht G., Ahrens M., Golf A., Haag G. M., Lordick F., Desuki A., Cazzaniga M., Ciardiello F., Milella M., Koyama T., Hirooka Y., Okamoto W., Aogi K., Kuboki Y., Lee J., Kim S. -B., Ahn M. -J., Chang J. H., Kim Y. -M., Nam D. -H., Park J. -S., Paz-Ares L., Moreno V., Cervantes A., Calvo M., Falcon A., Gonzalez A., Martinez Bueno A., Garcia-Corbacho J., Longo F., Yen C. -J., Chen J. -S., Hou M. -F., Chao Y., Rau K. -M., Chiu T. -J., Feng Y. -H., Hsu C. -H., Huang W. -T., Lai K. -M., Yeh S. -P., Palmer D., Welsh L., Plummer R., Bilen M., Arrowsmith E., Spigel D. R., Zandberg D. P., Doroshow D., Lu-Emerson C., Moezi M., Paulson S., Reardon D., Ward P., Chaves J., Grigg C., Hussein A., Manda S., Monticelli M., Qamar R., Richey S. L., Tamura D., Wilks S., Pant, S, Schuler, M, Iyer, G, Witt, O, Doi, T, Qin, S, Tabernero, J, Reardon, D, Massard, C, Minchom, A, Lugowska, I, Carranza, O, Arnold, D, Gutierrez, M, Winter, H, Stuyckens, K, Crow, L, Najmi, S, Hammond, C, Thomas, S, Santiago-Walker, A, Triantos, S, Sweiti, H, Loriot, Y, Greco, M, Coward, J, Joshua, A, Karapetis, C, Hart, C, Zhang, A, Prenen, H, Goeminne, J, Machiels, J, Rottey, S, Corassa, M, Molin, G, Tiscoski, K, Jardim, D, Mak, M, Fu, W, Yao, H, Huang, J, Jiang, H, Chen, B, Yan, D, Yang, Y, Le Tourneau, C, Penel, N, Salas, S, Blay, J, Brachet, P, Durando, X, Emambux, S, Ravaud, A, Folprecht, G, Ahrens, M, Golf, A, Haag, G, Lordick, F, Desuki, A, Cazzaniga, M, Ciardiello, F, Milella, M, Koyama, T, Hirooka, Y, Okamoto, W, Aogi, K, Kuboki, Y, Lee, J, Kim, S, Ahn, M, Chang, J, Kim, Y, Nam, D, Park, J, Paz-Ares, L, Moreno, V, Cervantes, A, Calvo, M, Falcon, A, Gonzalez, A, Martinez Bueno, A, Garcia-Corbacho, J, Longo, F, Yen, C, Chen, J, Hou, M, Chao, Y, Rau, K, Chiu, T, Feng, Y, Hsu, C, Huang, W, Lai, K, Yeh, S, Palmer, D, Welsh, L, Plummer, R, Bilen, M, Arrowsmith, E, Spigel, D, Zandberg, D, Doroshow, D, Lu-Emerson, C, Moezi, M, Paulson, S, Ward, P, Chaves, J, Grigg, C, Hussein, A, Manda, S, Monticelli, M, Qamar, R, Richey, S, Tamura, D, Wilks, S, Pant S., Schuler M., Iyer G., Witt O., Doi T., Qin S., Tabernero J., Reardon D. A., Massard C., Minchom A., Lugowska I., Carranza O., Arnold D., Gutierrez M., Winter H., Stuyckens K., Crow L., Najmi S., Hammond C., Thomas S., Santiago-Walker A., Triantos S., Sweiti H., Loriot Y., Greco M. A., Coward J., Joshua A., Karapetis C., Hart C., Zhang A., Prenen H., Goeminne J. -C., Machiels J. -P., Rottey S., Corassa M., Molin G. Z. D., Tiscoski K., Jardim D. L. F., Mak M., Fu W., Yao H., Huang J., Jiang H., Chen B., Yan D., Yang Y., Le Tourneau C., Penel N., Salas S., Blay J. -Y., Brachet P. -E., Durando X., Emambux S., Ravaud A., Folprecht G., Ahrens M., Golf A., Haag G. M., Lordick F., Desuki A., Cazzaniga M., Ciardiello F., Milella M., Koyama T., Hirooka Y., Okamoto W., Aogi K., Kuboki Y., Lee J., Kim S. -B., Ahn M. -J., Chang J. H., Kim Y. -M., Nam D. -H., Park J. -S., Paz-Ares L., Moreno V., Cervantes A., Calvo M., Falcon A., Gonzalez A., Martinez Bueno A., Garcia-Corbacho J., Longo F., Yen C. -J., Chen J. -S., Hou M. -F., Chao Y., Rau K. -M., Chiu T. -J., Feng Y. -H., Hsu C. -H., Huang W. -T., Lai K. -M., Yeh S. -P., Palmer D., Welsh L., Plummer R., Bilen M., Arrowsmith E., Spigel D. R., Zandberg D. P., Doroshow D., Lu-Emerson C., Moezi M., Paulson S., Reardon D., Ward P., Chaves J., Grigg C., Hussein A., Manda S., Monticelli M., Qamar R., Richey S. L., Tamura D., and Wilks S.

Abstract

Background: FGFR alterations are reported across various malignancies and might act as oncogenic drivers in multiple histologies. Erdafitinib is an oral, selective pan-FGFR tyrosine kinase inhibitor with activity in FGFR-altered advanced urothelial carcinoma. We aimed to evaluate the safety and activity of erdafitinib in previously treated patients with FGFR-altered advanced solid tumours. Methods: The single-arm, phase 2 RAGNAR study was conducted at 156 investigative centres (hospitals or oncology practices that are qualified oncology study centres) across 15 countries. The study consisted of four cohorts based on tumour histology and patient age; the results reported in this Article are for the primary cohort of the study, defined as the Broad Panel Cohort, which was histology-agnostic. We recruited patients aged 12 years or older with advanced or metastatic tumours of any histology (except urothelial cancer) with predefined FGFR1–4 alterations (mutations or fusions according to local or central testing). Eligible patients had disease progression on at least one previous line of systemic therapy and no alternative standard therapy available to them, and an Eastern Cooperative Oncology Group performance status of 0–1 (or equivalent for adolescents aged 12–17 years). Patients received once-daily oral erdafitinib (8 mg/day with provision for pharmacodynamically guided up-titration to 9 mg/day) on a continuous 21-day cycle until disease progression or intolerable toxicity. The primary endpoint was objective response rate by independent review committee according to Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1, or Response Assessment In Neuro-Oncology (RANO). The primary analysis was conducted on the treated population of the Broad Panel Cohort. This ongoing study is registered with ClinicalTrials.gov, number NCT04083976. Findings: Patients were recruited between Dec 5, 2019, and Feb 15, 2022. Of 217 patients treated with erdafitinib, 97 (45%) pa

Published
2023

5. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

Author

Paré, L., Pascual, T., Seguí, E., Teixidó, C., Gonzalez-Cao, M., Galván, P., Rodríguez, A., González, B., Cuatrecasas, M., Pineda, E., Torné, A., Crespo, G., Martin-Algarra, S., Pérez-Ruiz, E., Reig, Ò, Viladot, M., Font, C., Adamo, B., Vidal, M., Gaba, L., Muñoz, M., Victoria, I., Ruiz, G., Viñolas, N., Mellado, B., Maurel, J., Garcia-Corbacho, J., Molina-Vila, M Á, Juan, M., Llovet, J.M., Reguart, N., Arance, A., and Prat, A.

Published
2018
Full Text
View/download PDF

6. 125P Assessing the accuracy of multiple prognostic scores for immune checkpoint inhibitors (ICI) in patients with advanced solid tumors

Author

Garcia-Corbacho, J., primary, Indacochea, A., additional, Gonzalez, A., additional, Victoria Ruiz, I., additional, Moreno Fernández, D., additional, Pesantez Coronel, D.S., additional, Angelats, L., additional, Modrego, A., additional, Sanfeliu Torres, E., additional, Castillo, O., additional, Blasco, P., additional, Mezquita, L., additional, Vinolas Segarra, N., additional, Nogue Aliguer, M., additional, Adamo, B., additional, Baste Rotllan, N., additional, Sauri Nadal, T., additional, Juan, M., additional, Prat, A., additional, and Schettini, F., additional

Published
2022
Full Text
View/download PDF

7. 1295P EP0031 a next-generation selective RET inhibitor (SRI): Correlation of molecular and clinical responses in patients with RET alteration positive solid tumours naïve to or following prior SRI

Author

Garralda, E., Clark, L., Wang, J.S., Gianoukakis, A.G., Taylor, M.H., Morgensztern, D., Arnold, S.M., Spigel, D.R., Liu, S.V., Krebs, M.G., Forster, M.D., Garcia-Corbacho, J., Paz-Ares, L.G., Fisher, G., Brook, S., Patel, S., Arkenau, H-T., Overstreet, B., Yalamanchili, G., and Garrido Lopez, P.

Published
2024
Full Text
View/download PDF

8. Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA

Author

Hudecova, I, Smith, CG, Hansel-Hertsch, R, Chilamakuri, CS, Morris, JA, Vijayaraghavan, A, Heider, K, Chandrananda, D, Cooper, WN, Gale, D, Garcia-Corbacho, J, Pacey, S, Baird, RD, Rosenfeld, N, Mouliere, F, Hudecova, I, Smith, CG, Hansel-Hertsch, R, Chilamakuri, CS, Morris, JA, Vijayaraghavan, A, Heider, K, Chandrananda, D, Cooper, WN, Gale, D, Garcia-Corbacho, J, Pacey, S, Baird, RD, Rosenfeld, N, and Mouliere, F

Abstract

Current evidence suggests that plasma cell-free DNA (cfDNA) is fragmented around a mode of 166 bp. Data supporting this view has been mainly acquired through the analysis of double-stranded cfDNA. The characteristics and diagnostic potential of single-stranded and damaged double-stranded cfDNA in healthy individuals and cancer patients remain unclear. Here, through a combination of high-affinity magnetic bead-based DNA extraction and single-stranded DNA sequencing library preparation (MB-ssDNA), we report the discovery of a large proportion of cfDNA fragments centered at ∼50 bp. We show that these "ultrashort" cfDNA fragments have a greater relative abundance in plasma of healthy individuals (median = 19.1% of all sequenced cfDNA fragments, n = 28) than in plasma of patients with cancer (median = 14.2%, n = 21, P < 0.0001). The ultrashort cfDNA fragments map to accessible chromatin regions of blood cells, particularly in promoter regions with the potential to adopt G-quadruplex (G4) DNA secondary structures. G4-positive promoter chromatin accessibility is significantly enriched in ultrashort plasma cfDNA fragments from healthy individuals relative to patients with cancers (P < 0.0001), in whom G4-cfDNA enrichment is inversely associated with copy number aberration-inferred tumor fractions. Our findings redraw the landscape of cfDNA fragmentation by identifying and characterizing a novel population of ultrashort plasma cfDNA fragments. Sequencing of MB-ssDNA libraries could facilitate the characterization of gene regulatory regions and DNA secondary structures via liquid biopsy. Our data underline the diagnostic potential of ultrashort cfDNA through classification for cancer patients.

Published
2022

9. 44P Biomarker analysis from a phase Ib, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected (inj) into metastatic and primary liver tumors

Author

Hecht, J.R., primary, Peeters, M., additional, Martin Jimenez, M., additional, Pless, M., additional, Cubillo, A., additional, Garcia-Corbacho, J., additional, Mach, N., additional, Digklia, A., additional, Park, H., additional, Subbiah, V., additional, Gorski, K., additional, Anderson, A., additional, Liu, C., additional, Snyder, W., additional, and Chesney, J., additional

Published
2021
Full Text
View/download PDF

10. 1025TiP SOLTI-1904: Efficacy of spartalizumab across multiple cancer-types in patients with PD1-high mRNA expressing tumors defined by a single and pre-specified cutoff (ACROPOLI)

Author

Prat, A., primary, Paz-Ares, L., additional, Juan, M., additional, Felip, E., additional, Garralda, E., additional, González-Farré, B., additional, Arance Fernandez, A.M., additional, Martin-Liberal, J., additional, Gavilá, J., additional, López González, A., additional, Cejalvo, J.M., additional, Izarzugaza, Y., additional, Amillano, K., additional, Garcia-Corbacho, J., additional, Saura Manich, C., additional, Salvador, F., additional, Pascual, T., additional, Mesía, R., additional, Cervantes, A., additional, and Tabernero, J., additional

Published
2021
Full Text
View/download PDF

11. 92P First-results of the CLIMB360 study, a prospective molecular screening program across multiple cancer types based on circulating tumor DNA (ctDNA)

Author

Garcia-Corbacho, J., primary, Victoria Ruiz, I., additional, Angelats, L., additional, Indacochea, A., additional, Martínez-Vidal, J., additional, Sole Bentz, P., additional, Moreno, D., additional, Faull, I., additional, Campillo, M.L., additional, Muñoz, S., additional, Saurí, T., additional, Reguart Aransay, N., additional, Viñolas, N., additional, Esposito, F.M., additional, Mezquita, L., additional, Basté, N., additional, Oliveres, H., additional, Castillo, S., additional, Nogué, M., additional, and Prat, A., additional

Published
2021
Full Text
View/download PDF

12. 116P Real-world and in silico incidence of fibroblast growth factor receptor (FGFR) 1-4 molecular alterations across multiple cancer types

Author

Angelats, L., primary, Indacochea, A., additional, Ruiz, I. Victoria, additional, Moreno, D., additional, Bentz, P. Sole, additional, Mellado, B., additional, Pineda, E., additional, Garcia, L. Gaba, additional, Mateu, M. Muñoz, additional, Vidal, M., additional, Saurí, T., additional, Esposito, F.M., additional, Ferrer, L., additional, Martínez-Sáez, O., additional, Basté, N., additional, Ortega, V., additional, Jolis, L., additional, Mezquita, L., additional, Prat, A., additional, and Garcia-Corbacho, J., additional

Published
2021
Full Text
View/download PDF

13. 81P Baseline circulating CD4+PD1+high T cells (TCD4PD1H) as predictors of survival in patients (P) with solid tumors treated with immune-checkpoint inhibitors (ICI)

Author

Garcia-Corbacho, J., primary, Navarro, A.E. González, additional, Victoria, I., additional, Moreno, D., additional, Heredia, L., additional, Ortiz de Landázuri, I., additional, Díez-Guardia, V., additional, Sanfeliu, E., additional, Indacochea, A., additional, Angelats, L., additional, Viñolas, N., additional, Mellado, B., additional, Saurí, T., additional, Maurel, J., additional, Mezquita, L., additional, Pineda, E., additional, Basté, N., additional, Prat, A., additional, Juan, M., additional, and Schettini, F., additional

Published
2021
Full Text
View/download PDF

14. 406P Phase Ib safety and efficacy of nadunolimab/gemcitabine/carboplatin in mTNBC

Author

Lopez-Tarruella Cobo, S., Stradella, A., Ortega, P. Tolosa, Antolín-Novoa, S., Eslava, M. Santisteban, Garcia-Corbacho, J., Guerrero Zotano, A.L., Borrego, M. Ruiz, Caffarel, M. Muñoz, Losic, N., Gyllenbäck, E. Jaensson, Skoog, P., Johansen Blanco, H., Soto-Castillo, J.J., Alva Bianchi, M., Rendo, C. Reboredo, Casas, M., Caparroso, N., Montes, S. Bezares, and Ribas, I. Garcia

Published
2023
Full Text
View/download PDF

15. 1056P Efficacy of spartalizumab across multiple cancer types in patients with PD1-high mRNA expressing tumors (SOLTI-1904 ACROPOLI)

Author

Prat, A., Pascual, T., Juan, M., Paz-Ares, L., Felip, E., Garralda, E., Gonzalez-farre, B., Arance Fernandez, A.M., Martin-Liberal, J., López, A., Izarzugaza Peron, Y., Garcia-Corbacho, J., Saura Manich, C., Hierro, C., Sanfeliu Torres, E., Cejalvo, J.M., Salvador, F., Mesia Nin, R., Cervantes, A., and Tabernero, J.

Published
2023
Full Text
View/download PDF

16. Transcriptomic analysis of pre-treatment tissue samples to predict clinical benefit to durvalumab in HIV-infected cancer patients

Author

Bracht, JW, Gonzalez-Cao, M, Moran, T, Dalmau, J, Garcia-Corbacho, J, Bernabe, R, Juan, O, de Castro, J, Gimenez-Capitan, A, Blanco, R, Aldeguer, E, Rodriguez, S, Drozdowskyj, A, Argilaguet, J, Blanco, J, Prado, J, Brander, C, Carrillo, J, Clotet, B, Massuti, B, Provencio, M, Huang, CY, de las Casas, CM, Garzon, M, Cardona, AF, Arrieta, O, Meyerhans, A, Molina-Vila, MA, Martinez-Picado, J, and Rosell, R

Published
2020

19. P86.03 A Phase 2 Study of Erdafitinib in Patients with Advanced Solid Tumors and Fibroblast Growth Factor Receptor Gene Alterations

Author

Pant, S., primary, Tabernero, J., additional, Massard, C., additional, Hyman, D.M., additional, Witt, O., additional, Doi, T., additional, Qin, S., additional, Lu-Emerson, C., additional, Hargrave, D., additional, Garcia-Corbacho, J., additional, Little, S., additional, Tolbert, J., additional, Santiago-Walker, A., additional, Moy, C., additional, Hammond, C., additional, Lau, Y.Y., additional, Sweiti, H., additional, and Schuler, M., additional

Published
2021
Full Text
View/download PDF

21. 548P Molecular pre-screening using comprehensive gene panels offered by clinical trials (CT)

Author

Ruiz, I. Victoria, primary, Moreno, D., additional, Sole, P., additional, Gonzalez, B. Mellado, additional, Pineda, E., additional, Gaba, L., additional, Sauri, T., additional, Mileo, L. Ferrer, additional, Orrillo, M., additional, Maurel, J., additional, Oliveres, H., additional, Munoz-Mateu, M., additional, Losada, M.J. Vidal, additional, Saez, O. Martinez, additional, Chic, N., additional, Baste, N., additional, Segarra, N. Vinolas, additional, Reyes, R., additional, Prat, A., additional, and Garcia-Corbacho, J., additional

Published
2020
Full Text
View/download PDF

22. 347P Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC)

Author

Piccart, M., primary, Borrego, M. Ruiz, additional, Duhoux, F., additional, Arkenau, H-T., additional, Doger de Spéville, B., additional, Wildiers, H., additional, Campone, M., additional, Tosi, D., additional, Garcia-Corbacho, J., additional, Jimenez, B., additional, Romaní, S. Escrivá-de, additional, Wardley, A.M., additional, Tassone, P., additional, Boni, V., additional, Jerez, Y., additional, Aftimos, P.G., additional, Hennequin, A., additional, Amair-Pinedo, F., additional, Pellacani, A.U.E., additional, and Laurent, D.O., additional

Published
2020
Full Text
View/download PDF

23. 109P Subpopulations of peripheral blood lymphocytes and response to immunotherapy across cancer-types

Author

Garcia-Corbacho, J., primary, Gonzalez-Navarro, E.A., additional, Victoria Ruiz, I., additional, Arrufat, A., additional, Moreno Fernández, D., additional, Heredia, L., additional, Ortiz de Landázuri, I., additional, Segarra, N. Vinolas, additional, Mellado, B., additional, Sauri, T., additional, Maurel, J., additional, Gaba, L., additional, Pare, L., additional, Sanfeliu, E., additional, Baste, N., additional, Vidal Losada, M.J., additional, Arance Fernandez, A.M., additional, Reguart, N., additional, Prat, A., additional, and Juan, M., additional

Published
2020
Full Text
View/download PDF

24. 603TiP Phase II, open-label study of erdafitinib in adult and adolescent patients (pts) with advanced solid tumours harboring fibroblast growth factor receptor (FGFR) gene alterations

Author

Schuler, M., primary, Tabernero, J., additional, Massard, C., additional, Iyer, G. Vasudeva, additional, Witt, O., additional, Doi, T., additional, Qin, S., additional, Lu-Emerson, C., additional, Hargrave, D., additional, Garcia-Corbacho, J., additional, Little, S., additional, Xia, Q., additional, Santiago-Walker, A., additional, Moy, C.H., additional, Hammond, C., additional, Lau, Y.Y., additional, Sweiti, H., additional, and Pant, S., additional

Published
2020
Full Text
View/download PDF

25. 1275P Extended follow-up of DURVAST trial: A phase II study evaluating durvalumab treatment in HIV-1-infected patients with solid tumours by the Spanish lung cancer group

Author

Cao, M. Gonzalez, primary, Moran, T., additional, Dalmau, J., additional, Garcia-Corbacho, J., additional, Bernabe, R., additional, Vidal, O.J. Juan, additional, de Castro Carpeño, J., additional, Blanco, R., additional, Drozdowskyj, A., additional, Meyerhans, A., additional, Blanco, J., additional, Prado, J.G., additional, Clotet, B., additional, Sureda, B. Massuti, additional, Pulla, M. Provencio, additional, Molina-Vila, M.A., additional, Martinez-Picado, J., additional, and Costa, R. Rosell, additional

Published
2020
Full Text
View/download PDF

27. An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours

Author

Arkenau, H.-T., primary, Italiano, A., additional, Mak, G., additional, Toulmonde, M., additional, Baird, R.D., additional, Garcia-Corbacho, J., additional, Plummer, R., additional, Flynn, M., additional, Forster, M., additional, Wilson, R.H., additional, Tosi, D., additional, Adenis, A., additional, Donaldson, K., additional, Posner, J., additional, Kawabata, I., additional, Arimura, A., additional, Deva, S., additional, and Spicer, J., additional

Published
2018
Full Text
View/download PDF

28. Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial evaluating the PD-L1 probody therapeutic CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors

Author

Plummer, R., primary, Sanborn, R.E., additional, de Vries, E.G.E., additional, Lorusso, P., additional, Arkenau, H.-T., additional, Uboha, N., additional, Wydmanski, J., additional, Fidler, M.J., additional, Boni, V., additional, Garcia-Corbacho, J., additional, Humphrey, R., additional, Will, M., additional, Autio, K.A., additional, El-Khoueiry, A.B., additional, Menke-van der Houven van Oordt, C.W., additional, and Thistlethwaite, F., additional

Published
2018
Full Text
View/download PDF

29. Preliminary results of PROCLAIM-CX-072: The first-in-human, dose-finding trial of PD-L1 probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors

Author

Boni, V., primary, Garcia-Corbacho, J., additional, Ott, P.A., additional, Cho, D.C., additional, Autio, K.A., additional, Uboha, N., additional, Spira, A.I., additional, Humphrey, R., additional, Will, M., additional, Naing, A., additional, Thistlethwaite, F., additional, de Vries, E.G.E., additional, and Arkenau, H.-T., additional

Published
2018
Full Text
View/download PDF

30. AVEVAC: A phase I-II trial with avelumab plus autologous dendritic cell (ADC) vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer (mCRC) patients (GEMCAD 16-02)

Author

Español Rego, M., primary, Alonso, V., additional, Aparicio, J., additional, Elez Fernandez, E., additional, Escudero, P., additional, Fernández-Martos, C., additional, Rodríguez, N., additional, Ruiz Casado, A., additional, Cid, J., additional, Cabezón, R., additional, Lozano, M., additional, Ginés, A., additional, Bianchi, L., additional, Garcia-Corbacho, J., additional, García de Albéniz, X., additional, Maurel, J., additional, and Benitez Ribas, D., additional

Published
2018
Full Text
View/download PDF

31. The first-in-human, dose-finding PROCLAIM-CX-072 trial to assess the antitumor activity and tolerability of the probody therapeutic CX-072 as monotherapy and in combination with ipilimumab or vemurafenib in solid advanced tumors and lymphomas

Author

Boni, V., primary, Garcia-Corbacho, J., additional, Feliu, J., additional, Wydmanski, J., additional, Horvath, Z., additional, Bondarenko, I., additional, Irving, B., additional, Will, M., additional, de Vries, E.G.E., additional, and Thistlethwaite, F., additional

Published
2017
Full Text
View/download PDF

32. CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study

Author

Powderly, J., primary, Patel, M.R., additional, Lee, J.J., additional, Brody, J., additional, Meric-Bernstam, F., additional, Hamilton, E., additional, Ponce Aix, S., additional, Garcia-Corbacho, J., additional, Bang, Y-J., additional, Ahn, M-J., additional, Rha, S.Y., additional, Kim, K-P., additional, Gil Martin, M., additional, Wang, H., additional, Lazorchak, A., additional, Wyant, T., additional, Ma, A., additional, Agarwal, S., additional, Tuck, D., additional, and Daud, A., additional

Published
2017
Full Text
View/download PDF

34. Abstract OT2-01-11: Phase II of POSEIDON: A phase Ib / randomized phase II trial of tamoxifen plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment

Author

Oliveira, M, primary, Baird, RD, additional, van Rossum, AGJ, additional, Beelen, K, additional, Garcia-Corbacho, J, additional, Mandjes, IAM, additional, Vallier, AL, additional, van Werkhoven, E, additional, Garrigós, L, additional, Kumar, S, additional, van Tinteren, H, additional, Muñoz, S, additional, Linossi, C, additional, Rosing, H, additional, Miquel, JM, additional, Schrier, M, additional, de Vries Schultink, A, additional, Saura, C, additional, Gallagher, WM, additional, Bernards, R, additional, Tabernero, J, additional, Cortés, J, additional, Caldas, C, additional, and Linn, SC, additional

Published
2017
Full Text
View/download PDF

35. A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function

Author

Azaro, A. (Analía), Rodon, J. (Jordi), Machiels, J., Rottey, S. (Sylvie), Damian, S. (Silvia), Baird, R.D. (Richard), Garcia-Corbacho, J. (Javier), Mathijssen, A.H.J. (Ron), Clot, P.-F. (Pierre-François), Wack, C. (Claudine), Shen, L. (Liji), de Jonge, M.J.A. (Maja J. A.), Azaro, A. (Analía), Rodon, J. (Jordi), Machiels, J., Rottey, S. (Sylvie), Damian, S. (Silvia), Baird, R.D. (Richard), Garcia-Corbacho, J. (Javier), Mathijssen, A.H.J. (Ron), Clot, P.-F. (Pierre-François), Wack, C. (Claudine), Shen, L. (Liji), and de Jonge, M.J.A. (Maja J. A.)

Abstract

Purpose: Limited data are available on cabazitaxel pharmacokinetics in patients with renal impairment. This open-label, multicenter study assessed cabazitaxel in patients with advanced solid tumors and normal or impaired renal function. Methods: Cohorts A (normal renal function: creatinine clearance [CrCL] >80 mL/min/1.73 m2), B (moderate renal impairment: CrCL 30 to <50 mL/min/1.73 m2) and C (severe impairment: CrCL <30 mL/min/1.73 m2) received cabazitaxel 25 mg/m2 (A, B) or 20 mg/m2 (C, co

Published
2016
Full Text
View/download PDF

36. A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function

Author

Azaro, A, Rodon, J, Machiels, JP, Rottey, S, Damian, S, Baird, R, Garcia-Corbacho, J, Mathijssen, Ron, Clot, PF, Wack, C, Shen, Lucy, de Jonge, Maja, Azaro, A, Rodon, J, Machiels, JP, Rottey, S, Damian, S, Baird, R, Garcia-Corbacho, J, Mathijssen, Ron, Clot, PF, Wack, C, Shen, Lucy, and de Jonge, Maja

Abstract

Purpose Limited data are available on cabazitaxel pharmacokinetics in patients with renal impairment. This open-label, multicenter study assessed cabazitaxel in patients with advanced solid tumors and normal or impaired renal function. Methods Cohorts A (normal renal function: creatinine clearance [CrCL] >80 mL/min/1.73 m(2)), B (moderate renal impairment: CrCL 30 to <50 mL/min/1.73 m(2)) and C (severe impairment: CrCL < 30 mL/min/1.73 m(2)) received cabazitaxel 25 mg/m(2) (A, B) or 20 mg/m(2) (C, could be escalated to 25 mg/m(2)), once every 3 weeks. Pharmacokinetic parameters and cabazitaxel unbound fraction (F-U) were assessed using linear regression and mixed models. Geometric mean (GM) and GM ratios (GMRs) were determined using mean CrCL intervals (moderate and severe renal impairment: 40 and 15 mL/min/1.73 m(2)) versus a control (90 mL/min/1.73 m(2)). Results Overall, 25 patients received cabazitaxel (median cycles: 3 [range 1-20]; Cohort A: 5 [2-13]; Cohort B: 3 [1-15]; and Cohort C: 5 [1-20]), of which 24 were eligible for pharmacokinetic analysis (eight in each cohort). For moderate and severe renal impairment versus normal renal function, GMR estimates were: clearance normalized to body surface area (CL/BSA) 0.95 (90% CI 0.80-1.13) and 0.89 (0.61-1.32); area under the curve normalized to dose (AUC/dose) 1.06 (0.88-1.27) and 1.14 (0.76-1.71); and FU 0.99 (0.94-1.04) and 0.97 (0.87-1.09), respectively. Estimated slopes of linear regression of log parameters versus log CrCL (renal impairment) were: CL/BSA 0.06 (-0.15 to 0.28); AUC/dose -0.07 (-0.30 to 0.16); and FU 0.02 (-0.05 to 0.08). Cabazitaxel safety profile was consistent with previous reports. Conclusions Renal impairment had no clinically meaningful effect on cabazitaxel pharmacokinetics.

Published
2016

37. CamBMT1: A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases (mets) for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy

Author

Baird, R., primary, Garcia-Corbacho, J., additional, Ramenatte, N., additional, Jonson, A., additional, Ahmad, S., additional, Smith, D.-M., additional, Qian, W., additional, Kumar, S., additional, Linossi, C., additional, Matys, T., additional, Graves, M., additional, Jodrell, D., additional, Caldas, C., additional, Pacey, S., additional, Whitfield, G., additional, Chalmers, A., additional, Jena, R., additional, Price, S., additional, Jefferies, S., additional, and Watts, C., additional

Published
2016
Full Text
View/download PDF

38. A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors

Author

Pacey, S., primary, Blackhall, F., additional, Garcia-Corbacho, J., additional, Lipplaa, A., additional, Fusi, A., additional, Kumar, S., additional, Hategan, M., additional, Derham, J., additional, Laviste, G., additional, Halford, S., additional, Foxton, C., additional, McLeod, R., additional, Wan, S., additional, and Talbot, D., additional

Published
2016
Full Text
View/download PDF

39. Abstract P4-14-26: Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including HER2-positive breast cancer patients with brain metastases

Author

Baird, RD, primary, Arkenau, H-T, additional, Deva, S, additional, Cresti, N, additional, Garcia-Corbacho, J, additional, Hogarth, L, additional, Frenkel, E, additional, Kawaguchi, K, additional, Arimura, A, additional, Donaldson, K, additional, Posner, J, additional, Sarker, D, additional, Jodrell, D, additional, Plummer, R, additional, Spicer, J, additional, and Italiano, A, additional

Published
2016
Full Text
View/download PDF

40. 611TiP - AVEVAC: A phase I-II trial with avelumab plus autologous dendritic cell (ADC) vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer (mCRC) patients (GEMCAD 16-02)

Author

Español Rego, M., Alonso, V., Aparicio, J., Elez Fernandez, E., Escudero, P., Fernández-Martos, C., Rodríguez, N., Ruiz Casado, A., Cid, J., Cabezón, R., Lozano, M., Ginés, A., Bianchi, L., Garcia-Corbacho, J., García de Albéniz, X., Maurel, J., and Benitez Ribas, D.

Published
2018
Full Text
View/download PDF

41. 436P - Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial evaluating the PD-L1 probody therapeutic CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors

Author

Plummer, R., Sanborn, R.E., de Vries, E.G.E., Lorusso, P., Arkenau, H.-T., Uboha, N., Wydmanski, J., Fidler, M.J., Boni, V., Garcia-Corbacho, J., Humphrey, R., Will, M., Autio, K.A., El-Khoueiry, A.B., Menke-van der Houven van Oordt, C.W., and Thistlethwaite, F.

Published
2018
Full Text
View/download PDF

43. 1141PD - CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study

Author

Powderly, J., Patel, M.R., Lee, J.J., Brody, J., Meric-Bernstam, F., Hamilton, E., Ponce Aix, S., Garcia-Corbacho, J., Bang, Y-J., Ahn, M-J., Rha, S.Y., Kim, K-P., Gil Martin, M., Wang, H., Lazorchak, A., Wyant, T., Ma, A., Agarwal, S., Tuck, D., and Daud, A.

Published
2017
Full Text
View/download PDF

46. Phase I Multicentre Tax-Torc Trial of the Dual Mtorc1/2 Inhibitor Azd2014 (A) Plus Weekly Paclitaxel (P) in Patients (Pts) with Solid Tumours (Crukd/12/013)

Author

Basu, B., primary, Roda-Perez, D., additional, Wong, H.H., additional, Sathiyayogan, N., additional, Parmar, M., additional, Turner, A., additional, Swales, K., additional, Stimpson, S., additional, Hall, E., additional, Hategan, M., additional, Garcia-Corbacho, J., additional, Yap, T.A., additional, Molife, L.R., additional, Jimenez, B., additional, Banerjee, S., additional, Kaye, S.B., additional, De Bono, J.S., additional, and Banerji, U., additional

Published
2014
Full Text
View/download PDF

48. 408TiP - CamBMT1: A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases (mets) for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy

Author

Baird, R., Garcia-Corbacho, J., Ramenatte, N., Jonson, A., Ahmad, S., Smith, D.-M., Qian, W., Kumar, S., Linossi, C., Matys, T., Graves, M., Jodrell, D., Caldas, C., Pacey, S., Whitfield, G., Chalmers, A., Jena, R., Price, S., Jefferies, S., and Watts, C.

Published
2016
Full Text
View/download PDF

49. Abstract P4-12-24: Phase I trial of S-222611, a dual tyrosine kinase inhibitor of EGFR and HER2, with preliminary evidence of efficacy in patients (pts) with heavily-pretreated HER2-positive metastatic breast cancer

Author

Baird, RD, primary, Cresti, N, additional, Beddowes, E, additional, Saggese, M, additional, Flynn, M, additional, Garcia Corbacho, J, additional, Gao, F, additional, Lemech, C, additional, Donaldson, K, additional, Posner, J, additional, Kawabata, I, additional, Forster, M, additional, Arkenau, HT, additional, Plummer, R, additional, Jodrell, D, additional, and Spicer, J, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results